<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01615731</url>
  </required_header>
  <id_info>
    <org_study_id>SU-05302012-10088</org_study_id>
    <nct_id>NCT01615731</nct_id>
  </id_info>
  <brief_title>Value of Mifepristone in Cervical Preparation Prior to Dilation and Evacuation 19-24 Weeks</brief_title>
  <official_title>Value of Mifepristone in Eliminating the Need for a Second Set of Osmotic Dilators Prior to Dilation and Evacuation Between 19-24 Weeks: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Santa Clara Valley Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A common practice for preparation for surgical abortion after 19 weeks gestation is the
      placement of multiple sets of osmostic dilators 1-2 days prior to the procedure. The
      investigators aim to study the addition of mifepristone as an adjunct to cervical dilation
      prior to abortion between 19-24 weeks gestation, and its potential to minimize the number of
      painful procedures and time in clinic (or away from work/home) that multiple sets of dilators
      can require. The investigators hypothesize that one set of dilators with mifepristone will
      result in similar procedure times and decreased &quot;total&quot; time as two sets of dilators.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedure Time</measure>
    <time_frame>Intraoperative Time</time_frame>
    <description>Measured as time from speculum insertion to removal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Procedure Time</measure>
    <time_frame>Measured at clinic visits and on OR day, over a 3 day period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Cervical Dilation</measure>
    <time_frame>Measured intra-operatively</time_frame>
    <description>Measured by estimate with bimanual exam and passage of largest dilator immediately prior to procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (EBL)</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>One adverse event: Estimated Blood Loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of Procedure by Blinded Surgeon</measure>
    <time_frame>Measured Immediately after procedure</time_frame>
    <description>Used a Visual Analogue Scale to determine the ease of procedure by blinded surgeon. The VAS ranges from 0-100. 0 being the easiest procedure the surgeon felt they had every performed and 100 being the most difficult procedure imaginable by the surgeon.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Perceived by Patient</measure>
    <time_frame>Measured pre-operatively (after misoprostol, immediately before transport to OR) and post-operatively (in recovery room, on average 1.5 hours post-operatively)</time_frame>
    <description>Used a Visual Analogue Scale to determine the pain perceived by the patient pre-operatively (after misoprostol, immediately before transport to OR) and post-operatively (in recovery room, on average 1.5 hours post-operatively). The VAS ranges from 0-100. 0 being no pain felt by the patient and 100 being the worst pain imaginable felt by the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Patient Experience</measure>
    <time_frame>Measured post operatively (at least 30 minutes, on average 1.5 hours) prior to discharge</time_frame>
    <description>Used a Visual Analogue Scale to determine the patient's overall satisfaction with her experience. The VAS ranges from 0-100. 0 being a worse than expected experience, 50 being what the patient expected and 100 being a better than expected experience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Intraoperatively and 2 weeks post operatively</time_frame>
    <description>uterine perforation, uterine injury, etc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Abortion, Induced</condition>
  <arm_group>
    <arm_group_label>Two sets of dilators</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two sets of osmotic dilators inserted 1 and 2 days pre-op</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mifepristone plus one set of dilators</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One set of dilators plus mifepristone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>200mg Mifepristone orally</description>
    <arm_group_label>Mifepristone plus one set of dilators</arm_group_label>
    <other_name>Danco, Mifeprex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hygroscopic cervical dilators</intervention_name>
    <description>Dilapan-S osmostic cervical dilators inserted through the internal os</description>
    <arm_group_label>Two sets of dilators</arm_group_label>
    <arm_group_label>Mifepristone plus one set of dilators</arm_group_label>
    <other_name>Dilapan-S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>400mcg buccal misoprostol 90 minutes pre-op</description>
    <arm_group_label>Two sets of dilators</arm_group_label>
    <arm_group_label>Mifepristone plus one set of dilators</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intra-amniotic digoxin</intervention_name>
    <description>1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
    <arm_group_label>Two sets of dilators</arm_group_label>
    <arm_group_label>Mifepristone plus one set of dilators</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years old

          -  Viable, Singleton pregnancy

          -  Voluntarily seeking abortion between 19 and 24wks gestation

          -  Able to give informed consent and comply with study protocol

          -  Fluent in English or Spanish

        Exclusion Criteria:

          -  Allergy to misoprostol or mifepristone
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kate A Shaw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Santa Clara Valley Medical Center</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Shaw KA, Shaw JG, Hugin M, Velasquez G, Hopkins FW, Blumenthal PD. Adjunct mifepristone for cervical preparation prior to dilation and evacuation: a randomized trial. Contraception. 2015 Apr;91(4):313-9. doi: 10.1016/j.contraception.2014.11.014. Epub 2014 Dec 12.</citation>
    <PMID>25499589</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2012</study_first_submitted>
  <study_first_submitted_qc>June 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2012</study_first_posted>
  <results_first_submitted>December 19, 2014</results_first_submitted>
  <results_first_submitted_qc>January 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 26, 2015</results_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Kate Ayers Shaw</investigator_full_name>
    <investigator_title>Clinical Instructor, Clinical Fellow</investigator_title>
  </responsible_party>
  <keyword>Mifepristone</keyword>
  <keyword>Induced Abortion</keyword>
  <keyword>Dilation and Evacuation</keyword>
  <keyword>Cervical preparation</keyword>
  <keyword>Osmotic dilators</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Two Sets of Dilators</title>
          <description>Two sets of osmotic dilators inserted 1 and 2 days pre-op
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
        </group>
        <group group_id="P2">
          <title>Mifepristone Plus One Set of Dilators</title>
          <description>One set of dilators plus mifepristone
Mifepristone: 200mg Mifepristone orally
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Two Sets of Dilators</title>
          <description>Two sets of osmotic dilators inserted 1 and 2 days pre-op
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
        </group>
        <group group_id="B2">
          <title>Mifepristone Plus One Set of Dilators</title>
          <description>One set of dilators plus mifepristone
Mifepristone: 200mg Mifepristone orally
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="6.5"/>
                    <measurement group_id="B2" value="27.7" spread="6.7"/>
                    <measurement group_id="B3" value="27.7" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Procedure Time</title>
        <description>Measured as time from speculum insertion to removal</description>
        <time_frame>Intraoperative Time</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Two Sets of Dilators</title>
            <description>Two sets of osmotic dilators inserted 1 and 2 days pre-op
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
          </group>
          <group group_id="O2">
            <title>Mifepristone Plus One Set of Dilators</title>
            <description>One set of dilators plus mifepristone
Mifepristone: 200mg Mifepristone orally
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Time</title>
          <description>Measured as time from speculum insertion to removal</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="5.1"/>
                    <measurement group_id="O2" value="11.8" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Procedure Time</title>
        <time_frame>Measured at clinic visits and on OR day, over a 3 day period</time_frame>
        <population>Data missing for two subjects in &quot;Mifepristone plus one set of dilators&quot; arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Two Sets of Dilators</title>
            <description>Two sets of osmotic dilators inserted 1 and 2 days pre-op
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
          </group>
          <group group_id="O2">
            <title>Mifepristone Plus One Set of Dilators</title>
            <description>One set of dilators plus mifepristone
Mifepristone: 200mg Mifepristone orally
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
          </group>
        </group_list>
        <measure>
          <title>Total Procedure Time</title>
          <population>Data missing for two subjects in &quot;Mifepristone plus one set of dilators&quot; arm.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165" spread="57"/>
                    <measurement group_id="O2" value="86" spread="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Cervical Dilation</title>
        <description>Measured by estimate with bimanual exam and passage of largest dilator immediately prior to procedure.</description>
        <time_frame>Measured intra-operatively</time_frame>
        <population>Data missing for one subject in &quot;Mifepristone plus one set of dilators&quot; arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Two Sets of Dilators</title>
            <description>Two sets of osmotic dilators inserted 1 and 2 days pre-op
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
          </group>
          <group group_id="O2">
            <title>Mifepristone Plus One Set of Dilators</title>
            <description>One set of dilators plus mifepristone
Mifepristone: 200mg Mifepristone orally
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Cervical Dilation</title>
          <description>Measured by estimate with bimanual exam and passage of largest dilator immediately prior to procedure.</description>
          <population>Data missing for one subject in &quot;Mifepristone plus one set of dilators&quot; arm.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-op Cervical Dilation 2 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-op Cervical Dilation 3 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Op Cervical Dilation 4 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Op Cervical Dilation 5 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events (EBL)</title>
        <description>One adverse event: Estimated Blood Loss</description>
        <time_frame>Intraoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Two Sets of Dilators</title>
            <description>Two sets of osmotic dilators inserted 1 and 2 days pre-op
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
          </group>
          <group group_id="O2">
            <title>Mifepristone Plus One Set of Dilators</title>
            <description>One set of dilators plus mifepristone
Mifepristone: 200mg Mifepristone orally
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (EBL)</title>
          <description>One adverse event: Estimated Blood Loss</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" spread="31"/>
                    <measurement group_id="O2" value="63" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ease of Procedure by Blinded Surgeon</title>
        <description>Used a Visual Analogue Scale to determine the ease of procedure by blinded surgeon. The VAS ranges from 0-100. 0 being the easiest procedure the surgeon felt they had every performed and 100 being the most difficult procedure imaginable by the surgeon.</description>
        <time_frame>Measured Immediately after procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Two Sets of Dilators</title>
            <description>Two sets of osmotic dilators inserted 1 and 2 days pre-op
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
          </group>
          <group group_id="O2">
            <title>Mifepristone Plus One Set of Dilators</title>
            <description>One set of dilators plus mifepristone
Mifepristone: 200mg Mifepristone orally
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
          </group>
        </group_list>
        <measure>
          <title>Ease of Procedure by Blinded Surgeon</title>
          <description>Used a Visual Analogue Scale to determine the ease of procedure by blinded surgeon. The VAS ranges from 0-100. 0 being the easiest procedure the surgeon felt they had every performed and 100 being the most difficult procedure imaginable by the surgeon.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="23" upper_limit="52"/>
                    <measurement group_id="O2" value="30" lower_limit="18" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Perceived by Patient</title>
        <description>Used a Visual Analogue Scale to determine the pain perceived by the patient pre-operatively (after misoprostol, immediately before transport to OR) and post-operatively (in recovery room, on average 1.5 hours post-operatively). The VAS ranges from 0-100. 0 being no pain felt by the patient and 100 being the worst pain imaginable felt by the patient.</description>
        <time_frame>Measured pre-operatively (after misoprostol, immediately before transport to OR) and post-operatively (in recovery room, on average 1.5 hours post-operatively)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Two Sets of Dilators</title>
            <description>Two sets of osmotic dilators inserted 1 and 2 days pre-op
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
          </group>
          <group group_id="O2">
            <title>Mifepristone Plus One Set of Dilators</title>
            <description>One set of dilators plus mifepristone
Mifepristone: 200mg Mifepristone orally
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Perceived by Patient</title>
          <description>Used a Visual Analogue Scale to determine the pain perceived by the patient pre-operatively (after misoprostol, immediately before transport to OR) and post-operatively (in recovery room, on average 1.5 hours post-operatively). The VAS ranges from 0-100. 0 being no pain felt by the patient and 100 being the worst pain imaginable felt by the patient.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subject Pain Pre-Op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="7" upper_limit="34"/>
                    <measurement group_id="O2" value="63" lower_limit="16" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject Pain Post-Op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="32"/>
                    <measurement group_id="O2" value="16" lower_limit="6" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Patient Experience</title>
        <description>Used a Visual Analogue Scale to determine the patient's overall satisfaction with her experience. The VAS ranges from 0-100. 0 being a worse than expected experience, 50 being what the patient expected and 100 being a better than expected experience.</description>
        <time_frame>Measured post operatively (at least 30 minutes, on average 1.5 hours) prior to discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Two Sets of Dilators</title>
            <description>Two sets of osmotic dilators inserted 1 and 2 days pre-op
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
          </group>
          <group group_id="O2">
            <title>Mifepristone Plus One Set of Dilators</title>
            <description>One set of dilators plus mifepristone
Mifepristone: 200mg Mifepristone orally
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Patient Experience</title>
          <description>Used a Visual Analogue Scale to determine the patient's overall satisfaction with her experience. The VAS ranges from 0-100. 0 being a worse than expected experience, 50 being what the patient expected and 100 being a better than expected experience.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="66" upper_limit="91"/>
                    <measurement group_id="O2" value="79" lower_limit="67" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>uterine perforation, uterine injury, etc.</description>
        <time_frame>Intraoperatively and 2 weeks post operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Two Sets of Dilators</title>
            <description>Two sets of osmotic dilators inserted 1 and 2 days pre-op
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
          </group>
          <group group_id="O2">
            <title>Mifepristone Plus One Set of Dilators</title>
            <description>One set of dilators plus mifepristone
Mifepristone: 200mg Mifepristone orally
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>uterine perforation, uterine injury, etc.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Procedure Delivery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cervical Injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RUpture of Membranes with Subsequent Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Two Sets of Dilators</title>
          <description>Two sets of osmotic dilators inserted 1 and 2 days pre-op
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
        </group>
        <group group_id="E2">
          <title>Mifepristone Plus One Set of Dilators</title>
          <description>One set of dilators plus mifepristone
Mifepristone: 200mg Mifepristone orally
Hygroscopic cervical dilators: Dilapan-S osmostic cervical dilators inserted through the internal os
Misoprostol: 400mcg buccal misoprostol 90 minutes pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cervical Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pre-Procedure Delivery</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Rupture of Membranes with Subsequent Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Failure of randomization with respect to assigning similar numbers of nulliparous women to both groups; inaccurate method for measurement of pre-operative cervical dilation; small size of cohort.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kate Shaw</name_or_title>
      <organization>Stanford University</organization>
      <phone>(650) 725-5986</phone>
      <email>kateshaw@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

